Peripheral Vascular Disease (PVD) News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Understanding peripheral artery disease
New Yale research on this painful condition, its mental health effects, and socially determined outcomes will help improve patients ’ quality of life. (Source: Yale Science and Health News)
Source: Yale Science and Health News - September 21, 2022 Category: Universities & Medical Training Source Type: news

ADHD Is Risk Factor for Cardiovascular Diseases
Significant link seen for ADHD with risk for any CVD, especially cardiac arrest, hemorrhagic stroke, peripheral vascular disease/arteriosclerosis (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - September 20, 2022 Category: Psychiatry Tags: Cardiology, Family Medicine, Internal Medicine, Neurology, Psychiatry, Journal, Source Type: news

Hispanic adults face barriers accessing care for peripheral artery disease
A new, Yale-led study finds that adults with Hispanic backgrounds are more likely to only receive care at later stages and at emergency departments. (Source: Yale Science and Health News)
Source: Yale Science and Health News - September 15, 2022 Category: Universities & Medical Training Source Type: news

Mayo Clinic Q & amp;A podcast: Early diagnosis of peripheral artery disease reduces risk of amputation, heart attack and stroke
Peripheral artery disease, or PAD, affects almost 10 million people in the U.S. Approximately one-third of patients will die within five years of a peripheral artery disease diagnosis, and 20% will experience a heart attack or stroke. What is it? Peripheral artery disease usually involves pain in the lower limbs caused by reduced blood flow due to narrowing of the arteries. Its symptoms, like reduced ability to walk due to leg pain, often are brushed… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 13, 2022 Category: Databases & Libraries Source Type: news

Mayo Clinic Minute: How is peripheral artery disease diagnosed?
Peripheral artery disease affects 8 –10 million people in the U.S., most over age 65. But it also affects younger people who have additional risk factors, such as diabetes, smoking, obesity and high blood pressure. Also, 30% of Black Americans will develop peripheral artery disease, compared to 20% each from non-Hispanic white, Hispanic or Native American backgrounds. Dr. Amy Pollak, a Mayo Clinic cardiologist, explains how physicians identify peripheral artery disease and why an early diagnosis can… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 1, 2022 Category: Databases & Libraries Source Type: news

What to Know About Peripheral Artery Disease —and Its Connection to Diabetes
When we think of clogged arteries, most of us think about the heart. “But buildup of fatty plaques can happen in any artery, including those that carry blood away from the heart,” says Dr. Samuel Kim, a preventive cardiologist and lipidologist at Weill Cornell Medicine in New York. The arteries that branch out and feed into our arms and legs make up the bulk of what we call peripheral arteries. And the narrowing in these vessels is referred to as peripheral artery disease (PAD), a common condition in which the legs or arms don’t receive sufficient blood flow. “Interestingly, arteries in our legs and...
Source: TIME: Health - August 11, 2022 Category: Consumer Health News Authors: Lala Tanmoy Das Tags: Uncategorized Disease freelance healthscienceclimate Source Type: news

Walking at Pace Inducing Ischemic Leg Symptoms Beneficial in PAD
THURSDAY, July 28, 2022 -- For individuals with peripheral artery disease, walking exercise at a pace inducing ischemic leg symptoms is beneficial compared with walking exercise without ischemic leg symptoms, according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 28, 2022 Category: Pharmaceuticals Source Type: news

Home Exercise for Leg PAD Patients: 'No Pain, No Gain'
(MedPage Today) -- People with lower extremity peripheral artery disease (PAD) needed exercise training to be intense and painful in order to improve their walking, according to a post-hoc analysis of the LITE trial. Home-based walking exercise... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - July 27, 2022 Category: Primary Care Source Type: news

For Patients With Peripheral Artery Disease, Pain Can Be Gain For Patients With Peripheral Artery Disease, Pain Can Be Gain
Walking even when their legs hurt made a significant positive difference for people with peripheral artery disease.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - July 27, 2022 Category: Internal Medicine Tags: Family Medicine/Primary Care News Source Type: news

Have Leg Artery Disease? Walk Until It Hurts
WEDNESDAY, July 27, 2022 -- That phrase " no pain, no gain " might truly apply to people with peripheral artery disease (PAD), a new study finds. Researchers found that people with PAD who walked at pace that caused discomfort or even pain improved... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 27, 2022 Category: General Medicine Source Type: news

Peripheral artery disease can signal cardiovascular trouble for heart, brain and legs
If you have not heard of peripheral artery disease, or PAD, you are not alone. While clinicians and health organizations have made headway in raising awareness that heart disease is the No. 1 cause of death worldwide, PAD — despite being part of cardiovascular disease — is not as well-known. PAD affects 8 –10 million people in the U.S., most over the age of 65. But it also affects younger people who have additional risk… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - July 7, 2022 Category: Databases & Libraries Source Type: news

FDA Okays IN.PACT 018 Drug-Coated Balloon for PAD FDA Okays IN.PACT 018 Drug-Coated Balloon for PAD
Medtronic ' s device gives physicians the option to treat peripheral artery disease via femoral or radial access.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 27, 2022 Category: Cardiology Tags: Cardiology News Alert Source Type: news

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

Home Walking Program Eases Peripheral Artery Disease Limitations
(MedPage Today) -- Motivating patients with peripheral artery disease (PAD) and intermittent claudication to start walking at home improved their exercise capacity, the MOSAIC trial showed. Six-minute walk distance improved by 16.7 m more with... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 12, 2022 Category: Cardiology Source Type: news

Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news